<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37704">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615691</url>
  </required_header>
  <id_info>
    <org_study_id>261203</org_study_id>
    <nct_id>NCT02615691</nct_id>
  </id_info>
  <brief_title>BAX 855 Previously Untreated Patient (PUP)</brief_title>
  <official_title>Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity, and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) &lt; 6 Years With Severe Hemophilia A (FVIII &lt; 1%)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxalta US Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety, immunogenicity and hemostatic efficacy
      of PEGylated recombinant FVIII (BAX 855) in previously untreated (PUPs) and minimally
      treated patients (MTPs) with ≤ 3 EDs to ADVATE or BAX 855 &lt; 6 years of age with severe
      hemophilia A (baseline FVIII level &lt; 1%)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of FVIII inhibitor development</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate of Immune tolerance induction (ITI)</measure>
    <time_frame>Up to 33 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binding Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
    <description>Binding IgG and IgM antibodies to Factor VIII (FVIII), Factor VIII-Polyethylene glycol (PEG-FVIII) and Polyethylene glycol (PEG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Throughout Part A and Part B of the study, approximately 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>Throughout Part A and Part B of the study, approximately 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in clinical laboratory parameters</measure>
    <time_frame>Throughout Part A and Part B of the study, approximately 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) for prophylactic and on-demand treatment</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of BAX 855 infusions per bleeding episode</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall hemostatic efficacy rating</measure>
    <time_frame>24 h after initiation of treatment and at resolution of bleed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted consumption of BAX 855 per month, per year and per event</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions per month and per year</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of intra-, post- and perioperative hemostatic efficacy in case of surgery</measure>
    <time_frame>Surgery Day 0 up to postoperative Day 14 or discharge (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra- and postoperative blood loss in case of surgery</measure>
    <time_frame>Surgery Day 0 up to postoperative Day 14 or discharge (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Incremental recovery (IR) at baseline and over time</measure>
    <time_frame>Pre-infusion within 30 minutes; and post-infusion at 15-30 minutes and 24-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Half-life (T1/2) at baseline (optional)</measure>
    <time_frame>Post-infusion: 15-30 minutes and 24-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - Rate of partial success and failure of ITI</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - annualized bleeding rate (ABR) during ITI</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - Weight-adjusted consumption of BAX 855 per month and per year for each ITI regimen employed</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - Catheter-related complications</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) -Binding Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies</measure>
    <time_frame>Up to 33 months</time_frame>
    <description>Binding IgG and IgM antibodies to Factor VIII (FVIII), Factor VIII-Polyethylene glycol (PEG-FVIII) and Polyethylene glycol (PEG)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Previously untreated patients (PUPs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;6 years of age with severe hemophilia A (baseline Factor VIII (FVIII) level &lt; 1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)</description>
    <arm_group_label>Previously untreated patients (PUPs)</arm_group_label>
    <other_name>ADYNOVATE</other_name>
    <other_name>BAX855</other_name>
    <other_name>BAX 855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Participant is &lt; 6 years old at the time of screening 2. Participant is previously
        untreated or minimally treated 3. Participant has severe hemophilia A (Factor VIII (FVIII)
        &lt; 1%) 4. Participant is immune competent with a CD4+ count &gt; 200 cells/mm^3 5. Parent or
        legally authorized representative is willing and able to comply with the requirements of
        the protocol

          -  Additional inclusion criteria for Part B (Immune tolerance induction (ITI))

               1. Parent or legal representative has/have voluntarily provided signed informed
                  consent for ITI portion

               2. Participant has a confirmed inhibitor titer (≥ 0.6 Bethesda unit (BU)) and
                  requires ITI therapy

                  Exclusion Criteria:

               1. Participant has detectable FVIII inhibitory antibodies (≥ 0.6 BU)

               2. Participant has a history of FVIII inhibitory antibodies (≥ 0.6) at any time
                  prior to screening

               3. Participant has been diagnosed with an inherited or acquired hemostatic defect
                  other than hemophilia A

               4. Participant has been previously treated with fresh frozen plasma (FFP),
                  cryoprecipitate, any type of FVIII concentrate other than ADVATE or BAX 855 or
                  was administered ADVATE or BAX 855 for &gt; 3 EDs at any time prior to screening

               5. Participant has received any kind of blood-transfusion such as packed red blood
                  cells (PRBC), platelets or plasma at any time prior to screening

               6. The participant's weight is &lt; 5 kg

               7. Participant's platelet count is &lt; 100,000/mL

               8. Participant has known hypersensitivity towards mouse or hamster proteins, PEG or
                  Tween 80

               9. Participant has severe chronic hepatic dysfunction in his medical history or at
                  the time of screening

              10. Participant has severe renal impairment

              11. Participant has current or recent (&lt; 30 days) use of other PEGylated drugs prior
                  to study participation or is scheduled to use such drugs during study
                  participation

              12. Participant is scheduled to receive during the course of the study a systemic
                  immunomodulating drug other than anti-retroviral chemotherapy

              13. Participant has participated in another clinical study involving an
                  investigational product (IP) or investigational device within 30 days prior to
                  enrollment or is scheduled to participate in another clinical study involving an
                  IP or investigational device during the course of this study

              14. Parent or legally authorized representative has a medical, psychiatric, or
                  cognitive illness or recreational drug/alcohol use that, in the opinion of the
                  investigator, would affect subject safety or compliance

              15. Parent, legally authorized representative or participant are a member of the
                  team conducting this study or is in a dependent relationship with one of the
                  study team members

          -  Additional exclusion criteria for Part B (ITI)

               1. Spontaneous disappearance of the inhibitor prior to ITI

               2. FVIII inhibitor titer ≥ 0.6 BU is not confirmed by a second new blood sample and
                  determined at the central laboratory

               3. Inability or unwillingness to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Savage, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta, now part of Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celine Kefurt</last_name>
    <phone>+431201002476205</phone>
    <email>celine.kefurt@baxalta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Florida College Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's H</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Dis.Inst.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hemophilia Treatment Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies/Childrens Htl</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State MS Hershey Med Ctr</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Uni Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Georgi, EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SHAT Oncohaematology Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Marina, EAD</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Detske Hematologie</name>
      <address>
        <city>Praha</city>
        <zip>15500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU CAEN Hopital Cote de Nacre</name>
      <address>
        <city>Caen cedex 9</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Coeur Poumons</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>ROUEN Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese University Of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero F. Alessi</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I di Rom</name>
      <address>
        <city>Rome</city>
        <zip>144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang</city>
        <state>Kuala Lumpur</state>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital HRPB</name>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Georgetown</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Nur Zahirah</name>
      <address>
        <city>Terengganu</city>
        <zip>20400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KKH</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HOSPITAL A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chung- Ho Memorial Hosp</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial</name>
      <address>
        <city>Patumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SI Inst of Blood and TMedNAMSU</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Royal H. for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evelina Children's Hosp</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>November 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
